Journal
LANCET NEUROLOGY
Volume 13, Issue 12, Pages 1241-1256Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(14)70144-9
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research [FPP216158]
- International Spinal Research Trust
- Natural Sciences and Engineering Research Council of Canada
- UK Medical Research Council (SNCF) [G1002055]
- International Spinal Research Trust [TR1004_01]
- Henry Smith Charity [STR101]
- Wings for Life [WFL-GB-020/13]
- Rosetrees Trust [JS16/M276]
- International Foundation for Research in Paraplegia [P145]
- MRC [G1002055] Funding Source: UKRI
- International Spinal Research Trust [TRI004_01, STR101, STR108] Funding Source: researchfish
- Medical Research Council [G1002055] Funding Source: researchfish
- Rosetrees Trust [M276] Funding Source: researchfish
Ask authors/readers for more resources
Spinal cord injury is currently incurable and treatment is limited to minimising secondary complications and maximising residual function by rehabilitation. Improved understanding of the pathophysiology of spinal cord injury and the factors that prevent nerve and tissue repair has fuelled a move towards more ambitious experimental treatments aimed at promoting neuroprotection, axonal regeneration, and neuroplasticity. By necessity, these new options are more invasive. However, in view of recent advances in spinal cord injury research and demand from patients, clinicians, and the scientific community to push promising experimental treatments to the dinic, momentum and optimism exist for the translation of candidate experimental treatments to clinical spinal cord injury. The ability to rescue, reactivate, and rewire spinal systems to restore function after spinal cord injury might soon be within reach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available